Solena Therapeutics (SLNO) Stock Under Pressure But Upside is Huge

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is identified as a stock with significant upside potential, with multiple analysts maintaining bullish outlooks despite some mixed signals regarding its performance [1][2]. Group 1: Analyst Ratings and Price Targets - H.C. Wainwright raised the target price for SLNO from $110 to $120, indicating strong confidence in the stock's future performance [1]. - Wells Fargo analyst Derek Archila maintained a price target of $106, reflecting a positive sentiment towards the stock [1]. - Cantor Fitzgerald's Kristen Kluska reiterated a Buy rating with a price target of $123, further supporting the bullish outlook [1]. - Wolfe Research cut its price target from $75 to $60 but still maintains a Buy rating, suggesting a potential upside of 41.7% from current levels [2]. Group 2: Company Overview and Market Performance - Soleno Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases, founded in 1999 and based in Redwood City, California [3]. - The company's fourth-quarter sales of Vykat XR exceeded consensus expectations, although there are concerns regarding weaker new patient starts impacting stock performance [2]. - Wolfe Research noted that the current market valuation reflects a bear-case scenario for product uptake, while its base-case outlook anticipates a more moderate decline in new patient starts than currently priced in by the market [2].